Skip to main content
NCBI home page
Gut logoLink to Gut
. 1983 Feb;24(2):148–153. doi: 10.1136/gut.24.2.148

Somatostatin reduces gastric mucosal blood flow in normal subjects but not in patients with cirrhosis of the liver.

A Sonnenberg, C West
PMCID: PMC1420176  PMID: 6133813

Abstract

The effects of 1 and 4 micrograms/kg/h somatostatin on pentagastrin-stimulated gastric mucosal blood flow and acid secretion were investigated in 12 normal subjects and in 12 patients with cirrhosis of the liver. Each dose of somatostatin was given intravenously to six normal subjects and to six patients. Gastric mucosal blood flow was measured by the neutral red clearance of the stomach. Pentagastrin at a dose of 0.67 micrograms/kg/h stimulated acid secretion less in patients with cirrhosis of the liver than in normal subjects. In normal subjects 1 micrograms/kg/h somatostatin induced a parallel decline of gastric mucosal blood flow and gastric secretion; with 4 micrograms/kg/h somatostatin mucosal blood flow was inhibited more than gastric secretion. In patients with cirrhosis of the liver gastric mucosal blood flow remained unaffected by both doses of somatostatin, while acid secretion was slightly decreased. It is concluded that somatostatin can affect gastric mucosal blood flow independently of acid secretion. Somatostatin may be ineffective in the treatment of gastric haemorrhage in patients with cirrhosis of the liver.

Full text

PDF
148

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bosch J., Kravetz D., Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. Gastroenterology. 1981 Mar;80(3):518–525. [PubMed] [Google Scholar]
  2. Cowley D. J., Code C. F. Effects of secretory inhibitors on mucosal blood flow in nonsecreting stomach of conscious dogs. Am J Physiol. 1970 Jan;218(1):270–274. doi: 10.1152/ajplegacy.1970.218.1.270. [DOI] [PubMed] [Google Scholar]
  3. Elashoff J. D. Down with multiple t-tests. Gastroenterology. 1981 Mar;80(3):615–620. [PubMed] [Google Scholar]
  4. Jacobson E. D., Linford R. H., Grossman M. I. Gastric secretion in relation to mucosal blood flow studied by a clearance technic. J Clin Invest. 1966 Jan;45(1):1–13. doi: 10.1172/JCI105313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jaspan J., Polonsky K., Lewis M., Moossa A. R. Reduction in portal vein blood flow by somatostatin. Diabetes. 1979 Oct;28(10):888–892. doi: 10.2337/diab.28.10.888. [DOI] [PubMed] [Google Scholar]
  6. Kayasseh L., Gyr K., Keller U., Stalder G. A., Wall M. Somatostatin and cimetidine in peptic-ulcer haemorrhage. A randomised controlled trial. Lancet. 1980 Apr 19;1(8173):844–846. doi: 10.1016/s0140-6736(80)91352-5. [DOI] [PubMed] [Google Scholar]
  7. Keller U., Sonnenberg G. E., Kayasseh L., Gyr K., Perruchoud A. Dosisabhängigkeit der Wirkung von Somatostatin auf die splanchnische Durchblutung beim Menschen. Schweiz Med Wochenschr. 1979 Apr 21;109(16):595–596. [PubMed] [Google Scholar]
  8. Knight S. E., McIsaac R. L., Rennie C. D. The effect of histamine and histamine antagonists on gastric acid secretion and mucosal blood flow in man. Br J Surg. 1980 Apr;67(4):266–268. doi: 10.1002/bjs.1800670412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Konturek S. J., Tasler J., Cieszkowski M., Coy D. H., Schally A. V. Effect of growth hormone release-inhibiting hormone on gastric secretion, mucosal blood flow, and serum gastrin. Gastroenterology. 1976 May;70(5 PT1):737–741. [PubMed] [Google Scholar]
  10. Müller-Lissner S. A., Sonnenberg A., Blum A. L. Does gastric aminopyrine clearance reflect gastric mucosal blood flow or parietal cell function? Gut. 1981 Dec;22(12):997–1002. doi: 10.1136/gut.22.12.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rosenthal J., Escobar-Jimenez F., Raptis S. Prevention by somatostatin of rise in blood pressure and plasma renin mediated by beta-receptor stimulation. Clin Endocrinol (Oxf) 1977 Jun;6(6):455–462. doi: 10.1111/j.1365-2265.1977.tb03329.x. [DOI] [PubMed] [Google Scholar]
  12. Sacks H., Terry L. C. Clearance of immunoreactive somatostatin by perfused rat liver. J Clin Invest. 1981 Feb;67(2):419–429. doi: 10.1172/JCI110050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sonnenberg G. E., Keller U., Perruchoud A., Burckhardt D., Gyr K. Effect of somatostatin on splanchnic hemodynamics in patients with cirrhosis of the liver and in normal subjects. Gastroenterology. 1981 Mar;80(3):526–532. [PubMed] [Google Scholar]
  14. Thulin L., Tydén G., Samnegård H., Muhrbeck O., Efendić S. Treatment of bleeding oesophageal varices with somatostatin. Acta Chir Scand. 1979;145(6):395–398. [PubMed] [Google Scholar]
  15. Wahren J. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus. Lancet. 1976 Dec 4;2(7997):1213–1216. doi: 10.1016/s0140-6736(76)91142-9. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES